文献速递湿疹皮炎与荨麻疹

阿布昔替尼对中重度特应性皮炎患者报告结局的影响:III期研究及长期扩展JADE EXTEND结果

Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-07-17

JADE EXTEND长期扩展研究纳入既往III期试验中完成安慰剂或阿布昔替尼200/100 mg每日一次治疗的患者,随机接受阿布昔替尼200或100 mg每日一次治疗至第48周。第48周时,200 mg组和100 mg组DLQI 0/1应答率分别为44%和34%,POEM评分≥4分改善率分别为90%和77%。长期阿布昔替尼治疗使中重度AD患者报告的症状和生活质量获得临床意义改善。

要点

  • 第48周DLQI 0/1应答率:阿布昔替尼200 mg组44%,100 mg组34%。
  • 第48周POEM评分≥4分改善率:200 mg组90%,100 mg组77%。
  • DLQI均值由基线15.4/15.3降至第48周4.6(200 mg组)和5.9(100 mg组)。

核心结论

  • 在中重度AD患者中,长期阿布昔替尼治疗使患者报告的症状(包括生活质量)获得临床意义改善。

研究设计与样本

  • JADE EXTEND(NCT03422822)是一项正在进行的III期长期扩展研究,纳入来自既往阿布昔替尼AD试验的患者。
  • 本分析纳入完成JADE MONO-1、JADE MONO-2和JADE COMPARE中安慰剂或阿布昔替尼200/100 mg每日一次全治疗期后进入JADE EXTEND并随机接受阿布昔替尼200或100 mg每日一次的患者。
  • 患者报告终点评估至第48周,数据截止日期为2020年4月22日。

主要发现

  • 基线DLQI均值在阿布昔替尼200 mg组和100 mg组分别为15.4和15.3,对应对生活质量「非常大的影响」。
  • 第48周DLQI均值在阿布昔替尼200 mg组为4.6(对生活质量「小的影响」),100 mg组为5.9(「中等影响」)。
  • 基线POEM均值在阿布昔替尼200 mg组和100 mg组分别为20.4和20.5;第48周POEM均值分别为8.2和11.0。
  • 第48周患者报告应答:阿布昔替尼200 mg组和100 mg组DLQI 0/1分别为44%和34%,POEM评分≥4分改善分别为90%和77%。

关键数值与推荐

  • 患者报告终点包括DLQI评分0/1(AD对生活质量无影响)和POEM评分≥4分改善(临床意义改善)的比例。
  • DLQI 0/1应答率:阿布昔替尼200 mg组44% vs 100 mg组34%。
  • POEM评分≥4分改善率:阿布昔替尼200 mg组90% vs 100 mg组77%。

临床怎么用

  • 长期阿布昔替尼治疗可改善中重度AD患者报告的症状和生活质量,200 mg组在DLQI和POEM应答率上数值高于100 mg组。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abrocitinib improved signs and symptoms of moderate-to-severe atopic dermatitis (AD) at Weeks 12 and 16 in phase 3 studies, with a manageable safety profile. Patient-reported outcomes with long-term abrocitinib treatment were not reported. OBJECTIVE: To evaluate patient-reported outcomes with long-term abrocitinib treatment in patients with moderate-to-severe AD. METHODS: JADE EXTEND (NCT03422822) is an ongoing, phase 3, long-term extension study that enrolled patients from previous abrocitinib AD trials. This analysis includes patients from the phase 3 trials JADE MONO-1 (NCT03349060), JADE MONO-2 (NCT03575871) and JADE COMPARE (NCT03720470) who completed the full treatment period of placebo or abrocitinib (200 or 100 mg once daily) and subsequently entered JADE EXTEND and were randomised to receive once-daily abrocitinib 200 or 100 mg. Patient-reported endpoints to Week 48 included the proportion of patients who achieved Dermatology Life Quality Index (DLQI) scores of 0/1 (no effect of AD on quality of life [QoL]) and a ≥4-point improvement in Patient-Oriented Eczema Measure (POEM) score (clinically meaningful improvement). Data cut-off: April 22, 2020. RESULTS: Baseline DLQI mean scores were 15.4 and 15.3 in the abrocitinib 200- and 100-mg groups, respectively, which corresponded to a 'very large effect' on QoL; at Week 48, mean DLQI scores were lower with abrocitinib 200 mg (4.6; 'small effect' on QoL) and abrocitinib 100 mg (5.9; 'moderate effect' on QoL). Baseline POEM mean scores were 20.4 and 20.5 in the abrocitinib 200- and 100-mg groups, respectively; at Week 48, mean POEM scores were 8.2 and 11.0. Week 48 patient-reported responses with abrocitinib 200 mg and abrocitinib 100 mg were 44% and 34% for DLQI 0/1, and 90% and 77% for a ≥4-point reduction in POEM score. CONCLUSION: In patients with moderate-to-severe AD, long-term abrocitinib treatment resulted in clinically meaningful improvement in patient-reported symptoms of AD, including QoL.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Reich K, Silverberg JI, Papp KA, et al. Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol. 2023. PMID: 37319109. doi:10.1111/jdv.19254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。